Optimizing Phototesting and Investigating Photobiology of Visible Light
NCT ID: NCT05964907
Last Updated: 2025-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
14 participants
INTERVENTIONAL
2021-10-06
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Specific Aim 2: To investigate differential responses of subjects with different skin phototypes to VL+UVA1, including immediate and delayed erythema and pigmentation, and photodamage.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects
NCT04181476
Study for the RevLite Laser System for Facial Solar Lentigines
NCT02110108
Evaluation of Excessive UV Irradiation on Skin Aging by Multiphoton Laser Imaging and Biophysical Methods
NCT00372047
Combination Versus Laser Treatment Only
NCT03661697
Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics
NCT03007589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VL+UVA1
Participants will be treated with VL + UVA1 light source
Light Source B: Visible Light solar simulator (VL + UVA1)
Patients will be radiated with light source B (Visible light solar simulator)
Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)
Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Light Source B: Visible Light solar simulator (VL + UVA1)
Patients will be radiated with light source B (Visible light solar simulator)
Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)
Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fitzpatrick skin phototype (SPT) I-VI, 7 with SPT I-III and 7 with SPT IV-VI, with normal healthy skin
* Able to understand the requirements of the study and its associated risks
* Able to complete and sign a consent form
* Willing and able to refrain from any medications or herbal supplements during the duration of the study, unless permitted by the investigator
* Agrees to refrain from using any new topical skin care products, laundry detergents, or fragrances while participating in the study
* Has not had excessive sun exposure for 7 days prior to enrollment in the study
Exclusion Criteria
* History of relevant skin conditions such as atopic dermatitis, eczema, or sunburn on any part of the body
* History of photodermatoses or photosensitivity disorders
* History of melanoma or non-melanoma skin cancers
* Use of tanning parlors or exposure of the irradiated sites to sun light during the duration of the study
* Use of topical or systemic treatment that is likely to interfere with assessment, study results, or pose safety concerns
* Subjects with a tendency to bleed excessively
* Known allergies to anesthetics (lidocaine) or anaphylaxis treatment (epinephrine)
* History of hypertrophic scarring or keloid formation
* Use of any photosensitizing medication within the visible light range or additional medication at the discretion of the investigator \[examples include - but not limited to - thiazide diuretics, regular use of NSAIDs, hydroxychloroquine, or voriconazole
* A woman who is lactating, pregnant, or planning to become pregnant
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henry Ford Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Indermeet Kohli
Associate Scientist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henry Ford Medical Center
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14869
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.